Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in OncologyUma Prabhakar, David C. Blakey, Hiroshi Maeda et al.|Cancer Research|2013Cited by 1.5k
AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancerDavid S. Hong, A. Robert MacLeod, Anas Younes et al.|Science Translational Medicine|2015Cited by 438
A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical ModelsJeffrey L. Brown, David C. Blakey|Molecular Cancer Therapeutics|2010Cited by 153